Treatment with anti-Sclerostin antibody to stimulate mandibular bone formation.

about

Treatment with anti-Sclerostin antibody to stimulate mandibular bone formation.

Item

http://www.wikidata.org/entity/Q52664558

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Treatment with anti-Sclerostin antibody to stimulate mandibular bone formation.

@en

Treatment with anti-Sclerostin antibody to stimulate mandibular bone formation.

@nl

type

Item

label

Treatment with anti-Sclerostin antibody to stimulate mandibular bone formation.

@en

Treatment with anti-Sclerostin antibody to stimulate mandibular bone formation.

@nl

prefLabel

Treatment with anti-Sclerostin antibody to stimulate mandibular bone formation.

@en

Treatment with anti-Sclerostin antibody to stimulate mandibular bone formation.

@nl

P1476

Treatment with anti-Sclerostin antibody to stimulate mandibular bone formation.

@en

P2093

Jeffery Markey

http://www.w3.org/2001/XMLSchema#string

P Daniel Knott

http://www.w3.org/2001/XMLSchema#string

Tamara Alliston

http://www.w3.org/2001/XMLSchema#string

Tristan Fowler

http://www.w3.org/2001/XMLSchema#string

P2860

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

High bone mass in mice expressing a mutant LRP5 gene

Bone mineral density in sclerosteosis; affected individuals and gene carriers

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

Chromosome 21 and down syndrome: from genomics to pathophysiology

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment

Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.

Emerging therapeutic opportunities for skeletal restoration.

P304

1453-1460

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HED.25128

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Larry J Suva

Matthew Tamplen

P577

2018-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29522281

http://www.w3.org/2001/XMLSchema#string

P932

6037571

http://www.w3.org/2001/XMLSchema#string